Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of SPN-810M in Healthy Men
NCT02023606Phase 1Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Nov 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of molindone in intermittent explosive disorder (IED), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Urinary and fecal recoveries of total radioactivity at 10 days. Started Nov 2013; status: completed.
02
Drugs
molindone
03
Conditions
intermittent explosive disorder (IED)
Beyond the preview
Go deeper on NCT02023606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023606.